PRKD3 and breast carcinoma: Deletion of PRKD3 by CRISPR/Cas9 in breast cancer cell lines suppressed phosphorylation of ERK1 and c-MYC and led to reduced cell proliferation in vitro and tumor growth in vivo [67].